Novo Nordisk experienced a significant drop in its share price following Donald Trump’s claim that the price of its popular diabetes medication, Ozempic, may soon decrease in the United States. The company’s shares fell by five percent when the Copenhagen stock exchange opened at 9 a.m. on Friday.

The statement by Donald Trump regarding a potential price reduction for Ozempic in the US market seemingly triggered an immediate negative reaction from investors. This rapid decline highlights the sensitivity of pharmaceutical stock prices to pronouncements concerning drug pricing.

The drop occurred immediately after the market’s opening.